DMAA · Drugs Made In America Acquisition Corp.
$10.75
+0.03 (+0.23%)
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Additionally, the date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company's ability to continue as a going concern. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. Management plans to address this uncertainty through a Business Combination. There is no assurance that the Company's plans to raise capital or to consummate a Business Combination will be successful within the Combination Period.”View the 10-Q filed Aug 14, 2026
Market Cap
$260.98M
Shares
24.28M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
$5.94M
+2222.8%
FY2025
Diluted EPS
-$0.03
FY2024
Operating Cash Flow
-$539.19K
-213%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| $2.63M | $2.82M | $279.85K | |
| -$2.63M | -$2.82M | — | |
| $8.73M | $8.76M | — | |
| $8.73M | $8.76M | — | |
| $6.09M | $5.94M | -$279.85K | |
| USD/shares | — | — | -$0.03 |
| USD/shares | — | — | -$0.03 |
| shares | — | — | 8.57M |
| shares | — | — | 8.57M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Key facts
CIK
2028614
CUSIP
G2847J104
13F (30d)
46 filings
43 filers